A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID 19 in Hospitalized Adults

Site Image

Study Overview

This study is for patients in the hospital being treated for COVID-19

Remdesivir is approved to treat COVID-19. Some people who become sick with COVID-19 have serious disease and must be hospitalized. This can be fatal for a small percentage of patients. This trial will study the safety and efficacy of Remdesivir in combination with either Dexamethasone or Baracitinib in adults that are hospitalized with COVID-19.

Study Description

We are studying remdesivir in combination with either Baracitinib or Dexamethasone. 

There are 2 study groups. If you join the study, you will be randomly put into one of two groups. This is decided by chance. Out of every 2 people on this study, 1 will get Remdesivir/Dexamethasone and the other will get Remdesivir/Baracitinib.  When the study is over, we learn which combination works better in treating people with COVID-19. 

If you agree to join this study, we will first do some tests to make sure it is safe for you to join. This includes tests of your blood and a swab of the back of your throat (also known as an OP swab). 
Only hospitalized adults 18 years old and older who are not pregnant and not breastfeeding and who test positive for COVID-19 can join this study.

  • Study Identifier: 842784

Recruitment Status

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu